Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies
Nina Dedic, Heather Dworak, Courtney Zeni, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 24, pp. 13185-13185
Open Access | Times Cited: 77

Showing 1-25 of 77 citing articles:

Negative symptoms in schizophrenia: Newly emerging measurements, pathways, and treatments
Stephen R. Marder, Daniel Umbricht
Schizophrenia Research (2023) Vol. 258, pp. 71-77
Open Access | Times Cited: 42
Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders
Els F. Halff, Grazia Rutigliano, Anna Garcia-Hidalgo, et al.
Trends in Neurosciences (2022) Vol. 46, Iss. 1, pp. 60-74
Open Access | Times Cited: 59
Ligand recognition and G-protein coupling of trace amine receptor TAAR1
Zheng Xu, Lulu Guo, Jingjing Yu, et al.
Nature (2023) Vol. 624, Iss. 7992, pp. 672-681
Closed Access | Times Cited: 32
Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia
Eric D. Achtyes, Seth C. Hopkins, Nina Dedic, et al.
European Archives of Psychiatry and Clinical Neuroscience (2023) Vol. 273, Iss. 7, pp. 1543-1556
Open Access | Times Cited: 29
New Developments in the Treatment of Schizophrenia: An Expert Roundtable
Joshua T. Kantrowitz, Christoph U. Correll, Rakesh Jain, et al.
The International Journal of Neuropsychopharmacology (2023) Vol. 26, Iss. 5, pp. 322-330
Open Access | Times Cited: 23
Pharmacological Treatment of Cognitive Impairment Associated With Schizophrenia: State of the Art and Future Perspectives
Antonio Vita, Gabriele Nibbio, Sergio Barlati
Schizophrenia Bulletin Open (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 12
TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding
Nina Dedic, Lien Wang, Éva Hajós‐Korcsok, et al.
Molecular Metabolism (2024) Vol. 80, pp. 101883-101883
Open Access | Times Cited: 8
Trace amine-associated receptor 1 (TAAR1) agonism for psychosis: a living systematic review and meta-analysis of human and non-human data
Spyridon Siafis, Virginia Chiocchia, Malcolm Macleod, et al.
Wellcome Open Research (2024) Vol. 9, pp. 182-182
Open Access | Times Cited: 8
Overview of Novel Antipsychotic Drugs: State of the Art, New Mechanisms, and Clinical Aspects of Promising Compounds
Letizia Biso, Marco Carli, Marco Scarselli, et al.
Biomedicines (2025) Vol. 13, Iss. 1, pp. 85-85
Open Access | Times Cited: 1
Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials
Gia Han Le, Emily S. Gillissie, Taeho Greg Rhee, et al.
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 5, pp. 401-415
Closed Access | Times Cited: 16
Xanomeline-Trospium and Muscarinic Involvement in Schizophrenia
Neil S Kidambi, Omar H. Elsayed, Rif S. El‐Mallakh
Neuropsychiatric Disease and Treatment (2023) Vol. Volume 19, pp. 1145-1151
Open Access | Times Cited: 16
Discovery of a Novel Chemo-Type for TAAR1 Agonism via Molecular Modeling
Giancarlo Grossi, Naomi Scarano, Francesca Musumeci, et al.
Molecules (2024) Vol. 29, Iss. 8, pp. 1739-1739
Open Access | Times Cited: 6
Current Findings and Potential Mechanisms of KarXT (Xanomeline–Trospium) in Schizophrenia Treatment
Ali Azargoonjahromi
Clinical Drug Investigation (2024) Vol. 44, Iss. 7, pp. 471-493
Closed Access | Times Cited: 6
TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT1A receptor agonist SEP-363856
Marcus Saarinen, Ioannis Mantas, Ivana Flais, et al.
Neuropsychopharmacology (2022) Vol. 47, Iss. 13, pp. 2319-2329
Open Access | Times Cited: 26
Emerging Treatments in Schizophrenia
Christoph U. Correll, Anissa Abi‐Dargham, Oliver Howes
The Journal of Clinical Psychiatry (2022) Vol. 83, Iss. 1
Open Access | Times Cited: 22
Ulotaront, a Trace Amine-Associated Receptor 1/Serotonin 5-HT 1A Agonist, in Patients With Parkinson Disease Psychosis
Stuart Isaacson, Larry B. Goldstein, Rajesh Pahwa, et al.
Neurology Clinical Practice (2023) Vol. 13, Iss. 4
Open Access | Times Cited: 15
The role of rodent behavioral models of schizophrenia in the ongoing search for novel antipsychotics
Hugo Cano-Ramírez, Kurt L. Hoffman
Expert Opinion on Drug Discovery (2025), pp. 1-15
Closed Access
Novel Treatments for Schizophrenia
Steven M. Paul, Alan Breier
Oxford University Press eBooks (2025), pp. 231-246
Closed Access
The TAAR1 Agonist PCC0105004 Regulates Amygdala Synaptic Plasticity to Alleviate Anxiety‐Like Behaviors in Rats
Y Zhang, Wei Zhang, Linyao Yu, et al.
Pharmacology Research & Perspectives (2025) Vol. 13, Iss. 2
Open Access
New pharmacological approaches in the treatment of schizophrenia
Józef Muszyński, Agnieszka Bienert, Rasha Wafaie Mahmoud Elsorady, et al.
Pharmacological Reports (2025)
Closed Access
Receptors Involved in Mental Disorders and the Use of Clozapine, Chlorpromazine, Olanzapine, and Aripiprazole to Treat Mental Disorders
Ronald Mlambo, Jia Liu, Qian Wang, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 4, pp. 603-603
Open Access | Times Cited: 11
TAARs as Novel Therapeutic Targets for the Treatment of Depression: A Narrative Review of the Interconnection with Monoamines and Adult Neurogenesis
Taisiia S. Shemiakova, Evgeniya V. Efimova, Raul R. Gainetdinov
Biomedicines (2024) Vol. 12, Iss. 6, pp. 1263-1263
Open Access | Times Cited: 4
TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner
Sung Min Yang, Ayan Ghoshal, Jeffrey M. Hubbard, et al.
Neuropsychopharmacology (2023) Vol. 49, Iss. 7, pp. 1091-1103
Open Access | Times Cited: 9
Effects of acute and chronic administration of trace amine-associated receptor 1 (TAAR1) ligands on in vivo excitability of central monoamine-secreting neurons in rats
Daniil Grinchii, Marius C. Hoener, Talah Khoury, et al.
Molecular Psychiatry (2022) Vol. 27, Iss. 12, pp. 4861-4868
Open Access | Times Cited: 14
Reviewing Non-Dopaminergic Mechanisms for Positive and Negative Schizophrenia Symptom Management
Leslie Citrome, Jonathan M. Meyer
The Journal of Clinical Psychiatry (2023) Vol. 84, Iss. 4
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top